Diabetes & Metabolism Journal

Original Articles

Role of HbA1c in the Screening of Diabetes Mellitus in a Korean Rural Community: Jae Hyun Kim, Gun Woo Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Sang Baek Koh, Choon Hee Chung; Diabetes Metab J. 2012;36(1):37-42. Published online February 17, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.1.37

3,749 View
33 Download
11 Crossref

Background

Recently, the measurement of glycated hemoglobin (HbA1c) was recommended as an alternative to fasting plasma glucose or oral glucose tolerance tests for diagnosing diabetes mellitus (DM). In this study, we analyzed HbA1c levels for diabetes mellitus screening in a Korean rural population.

Methods

We analyzed data from 10,111 subjects from a Korean Rural Genomic Cohort study and generated a receiver operating characteristic curve to determine an appropriate HbA1c cutoff value for diabetes.

Results

The mean age of the subjects was 56.3±8.1 years. Fasting plasma glucose and 2-hour plasma glucose after 75 g oral glucose tolerance tests were 97.5±25.6 and 138.3±67.1 mg/dL, respectively. The mean HbA1c level of the subjects was 5.7±0.9%. There were 8,809 non-DM patients (87.1%) and 1,302 DM patients (12.9%). A positive relationship between HbA1c and plasma glucose levels and between HbA1c and 2-hour plasma glucose levels after oral glucose tolerance tests was found in a scatter plot of the data. Using Youden's index, the proper cutoff level of HbA1c for diabetes mellitus screening was 5.95% (sensitivity, 77%; specificity, 89.4%).

Conclusion

Our results suggest that the optimal HbA1c level for DM screening is 5.95%.

Citations

Citations to this article as recorded by

Hyperinsulinemia: an early biomarker of metabolic dysfunction
Rama A. Vaidya, Sharvari Desai, Panchali Moitra, Sheryl Salis, Shubhada Agashe, Rekha Battalwar, Anushree Mehta, Jagmeet Madan, Soumik Kalita, Shobha A. Udipi, Ashok B. Vaidya
Frontiers in Clinical Diabetes and Healthcare.2023;[Epub] CrossRef
A Novel Earwax Method to Measure Acute and Chronic Glucose Levels
Andrés Herane-Vives, Susana Espinoza, Rodrigo Sandoval, Lorena Ortega, Luis Alameda, Allan H. Young, Danilo Arnone, Alexander Hayes, Jan Benöhr
Diagnostics.2020; 10(12): 1069. CrossRef
Risk Factors for Underdiagnosis of Diabetes Based on the Korean National Health and Nutrition Examination Survey 2013-2015
Deulle Min, Eunhee Cho
Asia Pacific Journal of Public Health.2019; 31(5): 404. CrossRef
Recent advances of medical journals in Korea and and further development strategies: Is it possible for them to publish Nobel Prize-winning research?
Sun Huh
Journal of the Korean Medical Association.2018; 61(9): 524. CrossRef
The clinical value of HbA1c in combination with FPG in the early screening of the elderly with type 2 diabetes
Lihua Liu, Wenqing Chen, Minghua Dong, Lixia Jiang, Wei Qiu, Jian Li, Xiaoting Luo, Zhengchun Huang, Qin Wu, Qinfeng Wu, Shuiqin Chen, Lu Ou-Yang, Shumei Li, J.Q. Cheng, H.L. Moffitt, I. Kim, Z.T. Chi, J. Zhang
BIO Web of Conferences.2017; 8: 01030. CrossRef
The Cutoff Value of HbA1c in Predicting Diabetes and Impaired Fasting Glucose
Seyoung Kwon, Youngak Na
The Korean Journal of Clinical Laboratory Science.2017; 49(2): 114. CrossRef
Performance of HbA1c for the prediction of diabetes in a rural community in Korea
B. M. Song, H. C. Kim, J. Y. Lee, J.‐M. Lee, D. J. Kim, Y.‐H. Lee, I. Suh
Diabetic Medicine.2015; 32(12): 1602. CrossRef
The Relationship between BMI and Glycated Albumin to Glycated Hemoglobin (GA/A1c) Ratio According to Glucose Tolerance Status
Ji Hye Huh, Kwang Joon Kim, Byung-Wan Lee, Dong Wook Kim, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee, Marta Letizia Hribal
PLoS ONE.2014; 9(2): e89478. CrossRef
Additional perspectives on chronic kidney disease of unknown aetiology (CKDu) in Sri Lanka – lessons learned from the WHO CKDu population prevalence study
Jennifer Hoponick Redmon, Myles F Elledge, Donna S Womack, Rajitha Wickremashinghe, Kamani P Wanigasuriya, Roshini J Peiris-John, Joseph Lunyera, Kristin Smith, James H Raymer, Keith E Levine
BMC Nephrology.2014;[Epub] CrossRef
Diagnostic Efficiency of Hemoglobin A1c for Newly Diagnosed Diabetes and Prediabetes in Community-Based Chinese Adults Aged 40 Years or Older
Kai Liang, Yu Sun, Wen-juan Li, Xiu-ping Zhang, Cheng-qiao Li, Wei-fang Yang, Ze-qiang Ma, Ai-xia Ma, Hui-zhen Zheng, Jun Song, Peng Lin, Xin-guo Hou, Li Chen
Diabetes Technology & Therapeutics.2014; 16(12): 853. CrossRef
Diagnostic accuracy of HbA1c in diabetes between Eastern and Western
Shuang Yan, Siying Liu, Yashuang Zhao, Wencui Zhang, Xiaohui Sun, Jianing Li, Fuli Jiang, Jiaming Ju, Ning Lang, Yingqi Zhang, Weiyu Zhou, Qiang Li
European Journal of Clinical Investigation.2013; 43(7): 716. CrossRef

Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model: Mi Young Lee, Myoung Sook Shim, Bo Hwan Kim, Soon Won Hong, Ran Choi, Eun Young Lee, Soo Min Nam, Gun Woo Kim, Jang Yel Shin, Young Goo Shin, Choon Hee Chung; Diabetes Metab J. 2011;35(2):130-137. Published online April 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.2.130

3,713 View
64 Download
15 Crossref

Abstract PDF PubReader

Background

While there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clearly defined. In this study, we examined the effects of spironolactone, losartan, and a combination of these two drugs on albuminuria, renal VEGF expression, and inflammatory and oxidative stress markers in a type 2 diabetic rat model.

Methods

Thirty-three Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats were divided into four groups and treated with different medication regimens from weeks 25 to 50; OLETF diabetic controls (n=5), spironolactone-treated (n=10), losartan-treated (n=9), and combination of spironolactone- and losartan-treated (n=9).

Results

At week 50, the albumin-to-creatinine ratio was significantly decreased in the losartan and combination groups compared to the control OLETF group. No decrease was detected in the spironolactone group. There was a significant reduction in renal VEGF, transforming growth factor (TGF)-β, and type IV collagen mRNA levels in the spironolactone- and combination regimen-treated groups. Twenty-four hour urine monocyte chemotactic protein-1 levels were comparable in all four groups but did show a decreasing trend in the losartan and combination regimen groups. Twenty-four hour urine malondialdehyde levels were significantly decreased in the spironolactone- and combination regimen-treated groups.

Conclusion

These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate albuninuria by reducing renal VEGF expression. Also, simultaneous treatment with spironolactone and losartan may have protective effects against diabetic nephropathy by decreasing TGF-β and type IV collagen expression and by reducing oxidative stress in a type 2 diabetic rat model.

Citations

Citations to this article as recorded by

Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaali, John Prudente, Nosratola D. Vaziri, Bhupinder Singh, Wei Ling Lau
Pharmacology Research & Perspectives.2023;[Epub] CrossRef
Type 2 Diabetes Mellitus: Pathogenic Features and Experimental Models in Rodents
Inessa G. Gvazava, M. V. Karimova, A. V. Vasiliev, E. A. Vorotelyak
Acta Naturae.2022; 14(3): 57. CrossRef
Role of mineralocorticoid receptor antagonists in kidney diseases
Vishal Patel, Amit Joharapurkar, Mukul Jain
Drug Development Research.2021; 82(3): 341. CrossRef
Multi-strain probiotic supplement attenuates streptozotocin-induced type-2 diabetes by reducing inflammation and β-cell death in rats
Pei-Shan Hsieh, Hsieh-Hsun Ho, Shu Ping Tsao, Shih-Hung Hsieh, Wen-Yang Lin, Jui-Fen Chen, Yi-Wei Kuo, Shin-Yu Tsai, Hui-Yu Huang, Michael W. Greene
PLOS ONE.2021; 16(6): e0251646. CrossRef
Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin
Indira Purushothaman, Ian S. Zagon, Joseph W. Sassani, Patricia J. McLaughlin
Biochemical Pharmacology.2021; 192: 114712. CrossRef
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
Frontiers in Pharmacology.2021;[Epub] CrossRef
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats
Devesh Aggarwal, Gaaminepreet Singh
Naunyn-Schmiedeberg's Archives of Pharmacology.2020; 393(4): 615. CrossRef
Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model
Shih-Chun Yang, Ching-Yun Hsu, Wei-Ling Chou, Jia-You Fang, Shih-Yi Chuang
Molecules.2020; 25(23): 5713. CrossRef
Losartan improves renal function and pathology in obese ZSF-1 rats
Zhi Su, Deborah Widomski, Arthur Nikkel, Laura Leys, Marian Namovic, Diana Donnelly-Roberts, Murali Gopalakrishnan, Steve McGaraughty
Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(3): 281. CrossRef
Analyzing polymeric nanofibrous scaffold performances in diabetic animal models for translational chronic wound healing research
Nowsheen Goonoo, Archana Bhaw-Luximon
Nanotechnology Reviews.2017; 6(6): 583. CrossRef
Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy
Motonobu Nakamura, Nobuhiko Satoh, Masashi Suzuki, Haruki Kume, Yukio Homma, George Seki, Shoko Horita
Biochemical and Biophysical Research Communications.2015; 461(1): 154. CrossRef
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats
Amal Hofni, Mohamed A. El-Moselhy, Ashraf Taye, Mohamed M. Khalifa
European Journal of Pharmacology.2014; 744: 173. CrossRef
Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats
Jia-sheng Wu, Rong Shi, Jie Zhong, Xiong Lu, Bing-liang Ma, Tian-ming Wang, Bin Zan, Yue-ming Ma, Neng-neng Cheng, Fu-rong Qiu
Evidence-Based Complementary and Alternative Medicine.2013; 2013: 1. CrossRef
The use of animal models in diabetes research
Aileen JF King
British Journal of Pharmacology.2012; 166(3): 877. CrossRef
Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
Diabetes & Metabolism Journal.2012; 36(2): 128. CrossRef

First
Prev
Page of 1
Next
Last

Search